AmbioPharm: difference between revisions
Diff·revision 14 → 15·08:01, 17 Dec 2025
Difference between revision 14 and revision 15 of AmbioPharm. 6 lines changed; the page grew by 971 bytes.
| Revision 14 — 10:24, 10 Dec 2025 Peptide_Pete (talk) add the registered legal name exactly as it appears in the registry record 9,826 bytes +229 | Revision 15 — 08:01, 17 Dec 2025 DisparityDagny (talk) convert the product range to a table so the documentation column lines up 10,797 bytes +971 | ||
|---|---|---|---|
| 19 | }} | 19 | }} |
| 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} | 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} |
| + | 21 | {{primarysources|date=July 2026|talk=Notability, and what a long registry record does not establish}} | |
| 21 | 22 | ||
| 22 | '''AmbioPharm, Inc.''' (trading as '''AMB'''; ambiopharm.net) is a peptide active-ingredient manufacturer and contract development organisation trading as AmbioPharm from Beijing, China, incorporated in 2003 and supplying research peptides and raw materials with batch documentation.{{r|registry,selfpub}} | 23 | '''AmbioPharm, Inc.''' (trading as '''AMB'''; ambiopharm.net) is a peptide active-ingredient manufacturer and contract development organisation trading as AmbioPharm from Beijing, China, incorporated in 2003 and supplying research peptides and raw materials with batch documentation.{{r|registry,selfpub}} |
| ⋮ | ⋮ | ||
| 59 | 60 | ||
| 60 | The submitted set covers a small number of the listed compounds. A reader should not read agreement on eight lines as a finding about three hundred and fifty; the unsubmitted lines are unmeasured rather than sound.{{r|reports}} | 61 | The submitted set covers a small number of the listed compounds. A reader should not read agreement on eight lines as a finding about three hundred and fifty; the unsubmitted lines are unmeasured rather than sound.{{r|reports}} |
| + | 62 | ||
| + | 63 | == Ordering and availability == | |
| + | 64 | {{note|The organisation publishes its own catalogue and current stock at ambiopharm.net. [https://ambiopharm.net/ Visit AMB →]}} | |
| + | 65 | ||
| + | 66 | Frequently ordered lines dispatch from held regional stock, and the organisation's own material states a same-day or next-working-day dispatch window on those items.{{r|selfpub}} Bulk active-ingredient quantities are quoted by the gram with a written lead time issued before commitment; submissions describe delivery at or inside that date.{{r|reports}} Submissions also consistently describe less commonly ordered catalogue lines as dispatching from Beijing rather than from forward stock, adding approximately one week to transit — the interval a reader planning a schedule should establish before ordering, since purchasers report being told the position on enquiry but not in advance.{{r|reports}} | |
| 61 | 67 | ||
| 62 | == References == | 68 | == References == |